Zosano Pharma Corp Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-12-15: Form 8-K; Period of report 2017-12-12; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2017-12-01: Form 8-K; Period of report 2017-11-28; Description 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; Details 3.01.
- 2017-11-09: Form 8-K; Period of report 2017-11-09; Description 2.02 Results of Operations and Financial Condition.
- 2017-10-23: Form 8-K; Period of report 2017-10-20; Description 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-12-15 | 8-K | 2017-12-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 12, 2017, Mr. Bruce D. Steel advised the Board of Directors of Zosano Pharma Corporation (“Zosano”) that he would resign as a Class II independent director of Zosano, effective December 13, 2017. | d511371d8k.htm |
| 2017-12-01 | 8-K | 2017-11-28 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On November 28, 2017, Zosano Pharma Corporation (the “Company”) received written notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, as set forth in Listing Rule 5550(a)(2). | d502697d8k.htm |
| 2017-11-09 | 8-K | 2017-11-09 | 2.02 Results of Operations and Financial Condition | d492823d8k.htm | |
| 2017-10-23 | 8-K | 2017-10-20 | 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 3.02 The information contained above in Item 1.01 is hereby incorporated by reference into this Item 3.02. 8.01 On October 20, 2017, the Company issued a press release announcing the transaction with Lincoln Park. | d480591d8k.htm |
| 2017-10-04 | 8-K | 2017-10-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 3, 2017, our Board of Directors elected Kenneth R. Greathouse to our Board of Directors to serve as an independent Class II director. | d468258d8k.htm |
| 2017-08-23 | 8-K | 2017-08-17 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 In connection with the previous appointment of John Walker as our President and Chief Executive Officer effective as of August 9, 2017 (he served as Interim CEO from May 9, 2017 until August 9, 2017), we entered into an Employment Letter Agreement with him (the “Employment Agreement”). | d428377d8k.htm |
| 2017-08-10 | 8-K | 2017-08-10 | 2.02 Results of Operations and Financial Condition | d631900d8k.htm | |
| 2017-06-09 | 8-K | 2017-06-06 | 1.01 Entry into a Material Definitive Agreement | 1.01 On June 6, 2017, Zosano Pharma Corporation, a Delaware corporation (the “Company”) and the Company’s wholly owned subsidiary, ZP Opco, Inc., a Delaware corporation, entered into a Seventh Amendment to Lease (the “Seventh Amendment”) with BMR-34790 Ardentech Court LP, a Delaware limited partnership (“Landlord”). | d412748d8k.htm |
| 2017-06-05 | 8-K | 2017-05-31 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On May 31, 2017, we held our annual meeting of stockholders. | d290246d8k.htm |
| 2017-05-24 | 8-K/A | 2017-05-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 In connection with Mr. Walker’s appointment as the Company’s Interim Chief Executive Officer, on May 22, 2017, the Company and its subsidiary, ZP Opco, Inc. (the “Subsidiary”), entered into a Consulting Agreement with Mr. Walker, effective as of May 8, 2017 (the “Consulting Agreement”). | d404834d8ka.htm |
| 2017-05-09 | 8-K | 2017-05-08 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 8, 2017, Konstantinos Alataris resigned as President and Chief Executive Officer of the Company and the Company’s board of directors (the “Board”) has accepted his resignation, effective May 8, 2017. | d394264d8k.htm |
| 2017-05-05 | 8-K | 2017-05-02 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On May 2, 2017, Winnie Tso, who has been on a medical leave of absence since May 13, 2016, resigned as Chief Financial Officer of Zosano Pharma Corporation (the “Company”), effective immediately. | d392669d8k.htm |
| 2017-04-10 | 8-K | 2017-04-10 | 8.01 Other Events | 8.01 On April 10, 2017, the Company announced that it has scheduled its Annual Meeting of Stockholders (the “Annual Meeting”) to be held at our principal executive offices located at 34790 Ardentech Court, Fremont, California 94555, on May 31, 2017 at 8:30 a.m., Pacific time. | d370349d8k.htm |
| 2017-03-17 | 8-K | 2017-03-17 | 8.01 Other Events | 8.01 On March 17, 2017, Zosano Pharma Corporation (the “Company”) filed an Issuer Free Writing Prospectus relating to the Company’s Preliminary Prospectus dated March 13, 2017 (Registration No. 333-216410). | d323368d8k.htm |
| 2017-03-01 | 8-K | 2017-03-01 | 2.02 Results of Operations and Financial Condition | 2.02 On March 1, 2017, we issued a press released titled “Zosano Pharma Reports Fourth Quarter and Fiscal 2016 Financial Results and Business Update.” The press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 2.02. | d259364d8k.htm |
| 2017-02-13 | 8-K | 2017-02-13 | 8.01 Other Events | 8.01 On Monday, February 13, 2017, Zosano Pharma Corporation (the “Company”) issued a press release announcing the results of the Company’s ZOTRIP pivotal efficacy study of its lead product candidate, M207. | d345329d8k.htm |
| 2017-01-25 | 8-K | 2017-01-24 | 8.01 Other Events | 8.01 On January 24, 2017, Zosano Pharma Corporation received a letter from the Director of NASDAQ Listing Qualifications notifying the Company that it has regained compliance with the requirement of the NASDAQ Stock Market to maintain a minimum bid price of $1.00 per share. | d336031d8k.htm |